Jefferies Upgrades Abivax to Buy, Raises Price Target to $158

Benzinga Newsdesk www.benzinga.com Positive 88.8%

Neg 0% Neu 0% Pos 88.8%

Jefferies analyst Faisal Khurshid upgrades Abivax (NASDAQ:ABVX) from Hold to Buy and raises the price target from $108 to $158.